Eisai’s US subsidiary has appointed Lynn Kramer to the newly created position of chief clinical officer of Eisai Product Creation Systems.
He will be responsible for the approval of protocol designs of studies and selection of study regions and clinical sites.
Eisai said the appointment, which will also see him provide oversight of the design of proof of concept (POC) Studies for each of Eisai’s product creation units, would strengthen its clinical research.
In addition to his new responsibilities, Dr Kramer will continue to serve as president of Eisai’s Neuroscience and General Medicine Product Creation Unit, a position he has held since 2009.
Dr Kramer joined Eisai in 2007 as executive vice president of global clinical research and his roles since then have included COO of Eisai Medical Research and president of the Scientific and Operational Clinical Support unit.
Prior to joining Eisai, Dr Krammer had already spent more two decades in the pharmaceutical industry, serving at companies such as PAR Pharmaceutical, Ciba Geigy and Novartis.